ABC | Volume 114, Nº3, March 2020

Statement Brazilian Position Statement on Resistant Hypertension – 2020 Arq Bras Cardiol. 2020; 114(3):576-596 1. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education CommitteeoftheCouncilforHighBloodPressureResearch.Hypertension. 2008;51(6):1403-19. 2. Modolo R, de Faria AP, Almeida A, Moreno H. Resistant or refractory hypertension:aretheydifferent?CurrHypertensRep.2014;16(10):485. 3. Modolo R, de Faria AP, Sabbatini AR, Moreno H. Resistant hypertension revisited:definitionandtrueprevalence. JHypertens.2014;32(7):1546. 4. Martins LC, Figueiredo VN, Quinaglia T, Boer-Martins L, Yugar-Toledo JC, Martin JF, et al. Characteristics of resistant hypertension: ageing, body mass index,hyperaldosteronism,cardiachypertrophyandvascularstiffness.JHum Hypertens.2011;25(9):532-8. 5. Dudenbostel T, Siddiqui M, Oparil S, CalhounDA. RefractoryHypertension: A Novel Phenotype of Antihypertensive Treatment Failure. Hypertension. 2016;67(6):1085-92. 6. Moreno H, Jr, Coca A. Resistant and refractory hypertension: reflections on pathophysiologyandterminology.BloodPress.2012;21(4):209-10. 7. Yugar-Toledo JC, Brunelli V, Vilela-Martin JF, Fattori A, Moreno H. Controlled VersusUncontrolledResistantHypertension:AreThey intheSameBag?Curr HypertensRep.2018;20(3):1-6. 8. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation. 2016;134(6):441-50. 9. Scala LC, Magalhães LB , Machado A. Epidemiologia da hipertensão arterial sistêmica. In: Sociedade Brasileira de Cardiologia. Livro texto da SBC. 2a ed. SãoPaulo:Manole;2015.SãoPaulo;2015.p.780-5. 10. Nobre F, Ribeiro AB, Mion D Jr. [Control of arterial pressure in patients undergoing anti-hypertensive treatment in Brazil: Controlar Brazil]. Arq Bras Cardiol.2010;94(5):663-70. 11. Achelrod D, Wenzel U, Frey S. Systematic review and meta-analysis of the prevalenceofresistanthypertension intreatedhypertensivepopulations.Am JHypertens.2015;28(3):355-61. 12. BangaloreS,DavisBR,CushmanWC,PresselSL,MuntnerPM,CalhounDA, etal.Treatment-ResistantHypertensionandOutcomesBasedonRandomized TreatmentGroup inALLHAT.Am JMed.2017;130(4):439-48e9. 13. KriegerEM,DragerLF,GiorgiDMA,PereiraAC,Barreto-FilhoJAS,NogueiraAR, etal.SpironolactoneVersusClonidineasaFourth-DrugTherapy forResistant Hypertension: The ReHOT Randomized Study (Resistant Hypertension OptimalTreatment).Hypertension.2018;71(4):681-90. 14. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635-42. 15. Sarafidis PA, Bakris GL. Resistant hypertension: an overviewof evaluation and treatment. J Am Coll Cardiol. 2008;52(22):1749-57. 16. Sim JJ, Bhandari SK, Shi J, Liu IL, Calhoun DA, McGlynn EA, et al. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc. 2013;88(10):1099-107. 17. Cai A, Calhoun DA. Resistant Hypertension: An Update of Experimental and Clinical Findings. Hypertension. 2017;70(1):5-9. 18. Lazaridis AA, Sarafidis PA, Ruilope LM. Ambulatory Blood Pressure Monitoring in the Diagnosis, Prognosis, and Management of Resistant Hypertension: Still a Matter of our Resistance? Curr Hypertens Rep. 2015;17(10):78. 19. Salles GF, Cardoso CR, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med. 2008;168(21):2340-6. 20. Muxfeldt ES, Cardoso CR, Salles GF. Prognostic value of nocturnal blood pressure reduction in resistant hypertension. Arch Intern Med. 2009;169(9):874-80. 21. RoushGC, Fagard RH, Salles GF, Pierdomenico SD, Reboldi G, Verdecchia P, et al. Prognostic impact from clinic, daytime, and night-time systolic blood pressure in nine cohorts of 13,844 patients with hypertension. J Hypertens. 2014;32(12):2332-40; discussion 40. 22. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37(5):1236-41. 23. Chung CM, Cheng HW, Chang JJ, Lin YS, Hsiao JF, Chang ST, et al. Relationship between resistant hypertension and arterial stiffness assessed by brachial-ankle pulse wave velocity in the older patient. Clin Interv Aging. 2014 Sep 5;9:1495-502. 24. Brandao AA, Amodeo C, Alcantara C, Barbosa E, Nobre F, Pinto F, et al. I Luso-Brazilian Positioning on Central Arterial Pressure. Arq Bras Cardiol. 2017;108(2):100-8. 25. Salles GF, Cardoso CR, Fiszman R, Muxfeldt ES. Prognostic impact of baseline and serial changes in electrocardiographic left ventricular hypertrophy in resistant hypertension. AmHeart J. 2010;159(5):833-40. 26. Salles GF, Cardoso CR, Fiszman R, Muxfeldt ES. Prognostic importance of baseline and serial changes inmicroalbuminuria in patients with resistant hypertension. Atherosclerosis. 2011;216(1):199-204. References 10.5. Arteriovenous Fistula The creation of an arteriovenous fistula (AVF) can decrease BP by reducing total peripheral resistance and blood volume and inducing baroreflex inhibition and release of natriuretic peptides. 173 In a prospective randomized controlled trial, the creation of a central iliac AVF by an implantable device in 44 patients with RHTN led to significant reductions in 24-hour office and ambulatory systolic BP compared with pharmacological treatment. 174 However, there was a high rate of complications due to ipsilateral venous stenosis, requiring intervention in the AVF group. Further studies with a greater number of patients and with a comparison of AVF versus sham procedure are being conducted to verify the benefits of AVF in RHTN. 173 Erratum In the Statement “Posicionamento Brasileiro sobre Hipertensão Arterial Resistente – 2020” with DOI number: https:// doi.org/10.36660/abc.20200198 , published in the periodical Arquivos Brasileiros de Cardiologia, 114(3): 576-596, on page 582: in the figure 1 of the Portuguese version, where “hipertensão segundária” is mentioned, the correct is “Hipertensão arterial pseudorresistente”. In the English version, where “abnormal” is mentioned, right side of the figure 1, the correct is “normal”. 591